MYH2 (Myosin Heavy Chain 2, MyHC IIa) encodes the predominant myosin heavy chain isoform in fast-twitch oxidative skeletal muscle fibers. As a critical ATP-dependent motor protein driving muscle contraction, MYH2 is a structurally complex intracellular target for diseases including sarcopenia, congenital myopathies (e.g., myosin storage myopathy), cancer cachexia, and ALS. Current therapeutic development focuses on small molecule allosteric modulators, gene therapy, and antisense oligonucleotides to restore contractility or correct genetic defects. TarMart provides a comprehensive reagent toolkit to accelerate MYH2 drug discovery.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MYH2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MYH2 Recombinant Motor Domain / Full-Length Protein High purity (>95%), Endotoxin <1EU/μg, Sequence Verified. |
View MYH2 Products |
| Gene Delivery | MYH2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction (C2C12 myotube models). |
View MYH2 Products |
| Benchmark Ab | Anti-MYH2 (Research Grade) Recombinant monoclonal for Western/IHC/ICC detection and isoform specificity. |
View MYH2 Products |
| Validator | MYH2 siRNA Set For isoform-specific knockdown verification and off-target analysis. |
View MYH2 Products |
| Related Target: ACTA1 | Sarcomeric actin; direct binding partner for actomyosin ATPase assays. | View ACTA1 Products |
| Related Target: TNNT3 | Fast skeletal troponin T; regulatory complex for calcium-sensitization screening. | View TNNT3 Products |
| Related Target: MYH7 | Cardiac/beta-myosin heavy chain; critical paralog for selectivity counter-screening. | View MYH7 Products |
| Related Target: MSTN | Myostatin; synergistic pathway for muscle hypertrophy and atrophy prevention. | View MSTN Products |
| Related Target: MYH1 | Fast glycolytic isoform; co-expressed in fiber type transitions. | View MYH1 Products |
| Related Target: TRIM63 (MuRF1) | E3 ubiquitin ligase mediating MYH2 degradation in muscle atrophy. | View TRIM63 Products |
| Related Target: FBXO32 (Atrogin-1) | Key atrogene regulating muscle wasting upstream of myosin turnover. | View FBXO32 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (MYH2 vs MYH1/MYH4/MYH7) | Homolog panel proteins strictly verified by mass spec; isoform-specific immunogens available. |
| Intracellular Target Conformational Integrity & Aggregation | HEK293 expressed motor domains with native folding; high purity (>95%); optimized buffer with ATP/Mg2+ to maintain stability; aggregates removed by SEC. |
| ATPase Activity Quantification & Off-target Inhibition | Sequence-verified motor domain constructs with conserved ATP-binding pocket; suitable for malachite green or NADH-coupled assays; validated siRNA for specificity checks. |
| Lack of Muscle Cell Models | Premade MYH2 Lentivirus for stable transduction of C2C12 or primary myoblasts. |
| Disease Mutation Modeling (Myosin Storage Myopathy) | Custom mutant recombinant proteins (pathogenic variants) for mechanistic studies and rescue assays. |
Live MYH2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of skeletal muscle contractility is shifting from extracellular pathways (e.g., myostatin inhibition) toward direct sarcomeric modulation. MYH2, the predominant fast oxidative myosin heavy chain, represents a frontier target for diseases characterized by muscle weakness and atrophy. Early-stage small-molecule activator programs and gene therapy vectors for MYH2-related myopathies are advancing, driving demand for biochemical and cell-based assays using full-length and mutant MYH2 proteins. The next wave of R&D will focus on paralog-selective activators and mutation-specific rescue strategies. Additionally, emerging antisense oligonucleotide therapies targeting cryptic splice sites in myosin storage myopathy show preclinical promise.
Key Mutations & Functional Domains
Based on UniProt Q9UKX2:
-
Functional Domains:
- Myosin N-terminal SH3-like domain
- Myosin motor domain
- IQ motifs
-
Key Mutations:
- rs121434589: Associated with CMYO6 (cardiac myopathy?)
- rs143872329: Found in one patient with familial myopathy; uncertain significance.
- rs142586585: Variant in dbSNP.
Competitive Modality Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators | Cytokinetics, Astellas, and neuromuscular biotechs | Sarcopenia, ALS, Cancer Cachexia | ATPase screening using high-purity S1 motor domain proteins |
| Gene Therapy (AAV) | Sarepta, Solid Biosciences, rare disease consortia | Congenital Myopathy, Myosin Storage Myopathy | Transgene expression & functional rescue (mutant vs WT MYH2 lentivirus) |
| Antisense / Oligonucleotide | Ionis, Alnylam, academic consortia | Dominant Myopathies, Myosin Storage Myopathy | Knockdown validation (validated siRNA and lentivirus) |